QIAGEN launches QIAcube Connect MDx platform for automated sample processing in diagnostic labs • QIAcube Connect MDx carries CE-IVD marking in Europe and will be launched globally• Device allows labs [….]
Novel Microdevices Joins Baltimore’s LaunchPort™ Medtech Venture Center Manufacturing Innovative Diagnostic Products for Enhancing Patient Healthcare BALTIMORE (PRWEB) FEBRUARY 26, 2021 The LaunchPort™ announced today that Novel Microdevices (http://www.noveldx.com) has moved [….]
ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.
Numerous bacterium, viruses, fungi, and parasites can cause serious infections in people, and Virginia-based Aperiomics aims to catalog each one to provide doctors with the most accurate diagnostics information available.
John Newby is the CEO at Virginia Bio, the statewide non-profit trade association for the life science industry. Approximately 300 companies spanning biopharmaceuticals, medical devices, med tech, diagnostics, digital health, bioinformatics, agriculture, and industrial bio and related fields are based in Virginia, mainly clustered around research universities and medical institutions. Virginia Bio is the sole state affiliate and works closely with key national industry organizations BIO, AdvaMed, MDMA, PhRMA and We Work for Health.
Maryland’s Longhorn Vaccines & Diagnostics Set to Launch New Product that Could Revolutionize Molecular Testing
Longhorn Vaccines & Diagnostics, which has offices in Bethesda, Maryland, and San Antonio, Texas, has been at the forefront of the battle against COVID-19. And now, the innovative company has released its latest product, PrimeStore Analyte Transport Media (ATM)Ⓡ, which could revolutionize antigen and molecular testing by completely eliminating the need for RNA and DNA extraction.
Courtesy of Luke Daum, Chief Scientific Officer and Executive VP at Longhorn Vaccines and Diagnostics Good News – Featuring Johns Hopkins, Longhorn Vaccines and Diagnostics, and More… Across the country, [….]
Veteran Owned Diagnostics Supplier Tapped to Help alleviate COVID-19 Sample Collection Shortages April 28, 2020 Longhorn Vaccines & Diagnostics, located in Bethesda, Maryland, is a privately-held, veteran-run company that develops [….]
Six Johns Hopkins COVID-19 Programs that Reflect A Culture of Leadership from Clinical Research to Healthcare Innovation